Find Borax Solution manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

240 RELATED EXCIPIENT COMPANIES

397EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1330-43-4, Borax anhydrous, Borax glass, Borax, fused, Boric acid (h2b4o7), sodium salt, Boron sodium oxide (b4na2o7)
Molecular Formula
B4Na2O7
Molecular Weight
201.2  g/mol
InChI Key
UQGFMSUEHSUPRD-UHFFFAOYSA-N
FDA UNII
8191EN8ZMD

Borax Solution
1 2D Structure

Borax Solution

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane
2.1.2 InChI
InChI=1S/B4O7.2Na/c5-1-7-3-9-2(6)10-4(8-1)11-3;;/q-2;2*+1
2.1.3 InChI Key
UQGFMSUEHSUPRD-UHFFFAOYSA-N
2.1.4 Canonical SMILES
B1(OB2OB(OB(O1)O2)[O-])[O-].[Na+].[Na+]
2.2 Other Identifiers
2.2.1 UNII
8191EN8ZMD
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Disodium Borate, Heptahydrate

2. Disodium Borate, Monohydrate

3. Komex

4. Monosodium Metaborate

5. Sodium Borate

6. Sodium Borate (nabo2)

7. Sodium Diborate

8. Sodium Meta Borate

9. Sodium Metaborate

2.3.2 Depositor-Supplied Synonyms

1. 1330-43-4

2. Borax Anhydrous

3. Borax Glass

4. Borax, Fused

5. Boric Acid (h2b4o7), Sodium Salt

6. Boron Sodium Oxide (b4na2o7)

7. Na2b4o7

8. Sodium Tetraborate, Anhydrous

9. Sodiumtetraborate

10. Sodium Borate Anhydrous

11. Anhydrous Borax

12. Sodium Biborate

13. Fused Borax

14. Sodium Pyroborate

15. Sodium Borate, Anhydrous

16. 8191en8zmd

17. Sodium Tetraborate (na2b4o7)

18. Mfcd00081185

19. Boric Acid (h2b4o7), Disodium Salt

20. Disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane

21. 12267-73-1

22. Disodium;[oxido(oxoboranyloxy)boranyl]oxy-oxoboranyloxyborinate

23. Mfcd00163147

24. Komex

25. Borax, Anhydrous

26. Borax, Dehydrated

27. Sodium Boron Oxide

28. Rasorite 65

29. Fused Sodium Borate

30. Boric Acid, Disodium Salt

31. Sodium Borate [mi]

32. Unii-8191en8zmd

33. Borate-buffered Saline (5x)

34. Sodium Borate [who-dd]

35. Hsdb 5025

36. Sodium Tetraborate [hsdb]

37. Dtxsid101014358

38. Fr 28

39. Sodium Tetraborate [vandf]

40. Einecs 215-540-4

41. Mfcd07784974

42. Borates, Tetrasodium Salts, Anhydrous

43. Akos015903865

44. Akos030228253

45. Db14505

46. Borates, Tetra, Sodium Salts, Anhydrous

47. Borate, 0.5m Buffer Solution, Ph 8.0

48. Borate, 0.5m Buffer Solution, Ph 8.5

49. Borate, 0.5m Buffer Solution, Ph 9.0

50. Borate, 0.5m Buffer Solution, Ph 9.5

51. Sodium Tetraborate, Anhydrous, Puratronic

52. Ft-0696539

53. Sodium Borate, 0.5m Buffer Solution, Ph 8.0

54. Sodium Borate, 0.5m Buffer Solution, Ph 8.5

55. Sodium Borate, 0.5m Buffer Solution, Ph 9.0

56. Sodium Tetraborate,trace Metals Grade 99.95%

57. J-006292

58. Disodium Bicyclo[3.3.1]tetraboroxane-3,7-bis(olate)

59. 1310383-93-7

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 201.2 g/mol
Molecular Formula B4Na2O7
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count7
Rotatable Bond Count0
Exact Mass201.9811616 g/mol
Monoisotopic Mass201.9811616 g/mol
Topological Polar Surface Area92.3 Ų
Heavy Atom Count13
Formal Charge0
Complexity121
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count3
4 Drug and Medication Information
4.1 Therapeutic Uses

MEDICATION (VET): Has been used as antiseptic, detergent, astringent for mucous membrane

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 1537


MEDICATION (VET): Has been used as an exptl growth promoter in poultry feeds.

Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 50


/Exptl Ther:/ The in vivo spermicidal action of a pharmacological association consisting of 0.080 g of sodium tetraborate decahydrate, 0.075 g lactic acid, 0.020 g 8-hydroxyquinoline sulphate, 0.005 g sodiopropionate, and hydrosoluble excipient 1820 g polyethylene glycol in the form of vaginal containers, has been investigated. The study is part of a more general investigation of alternative systems to the use of estro-progestins. The experimental scheme applied in the present study provided for the use of this association in 28 volunteer couples who were definitely fertile and during the pre- and postovulatory periods. A normal postcoital test was carried out on each, with samples taken from the posterior fornix and cervical canal using a speculum. The results showed that the preparation possesses profound spermicidal activity and is therefore considered a useful alternative to oral contraceptives. /Sodium tetraborate decahydrate/

PMID:6787483 Oriz C et al; Minerva Ginecol 33 (1): 113-6 (1981)


4.2 Drug Indication

No FDA- or EMA-approved therapeutic indications on its own.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Boric acid exhibits minimal bacteriostatic and antifungal activities. Boric acid is likely to mediate antifungal actions at high concentrations over prolonged exposures.


5.2 Absorption, Distribution and Excretion

Absorption

Boric acid is well absorbed from the gastrointestinal tract, open wounds, and serous cavities but displays limited absorption in intact skin. Following intraperitoneal injection in mice, the peak concentration was reached in about 1.0-1.5 hr in the brain whereas the value was 0.5 hr in other tissues.


Route of Elimination

Regardless the route of administration, boric acid predominantly undergoes rapid renal excretion of >90% of total administered dose as unchanged form. Small amounts are also excreted into sweat, saliva, and feces. Following administration as ointment, urinary excretion of boric acid accounted for only 1% of the administered dose.


Volume of Distribution

Volume of distribution ranges from 0.17 to 0.5 L/kg in humans, where large amounts of boric acid are localized in brain, liver, and kidney.


Clearance

A case report of acute boric acid poisoning following oral ingestion of 21 g of boric acid presents the total body clearance of 0.99 L/h before hemodialysis.


The pharmacokinetics of boron was studied in rats by administering a 1 mL oral dose of sodium tetraborate solution to several groups of rats (n=20) at eleven different dose levels ranging from 0-0.4 mg/100 g bw as boron. Twenty-four-hour urine samples were collected after boron administration. After 24 hr the average urinary recovery rate for this element was 99.6-7.9. The relationship between boron dose and excretion was linear (r=0.999) with a regression coefficient of 0.954. This result suggests that the oral bioavailability (F) of boron was complete. Another group of rats (n=10) was given a single oral /intubation/ of 2 mL of sodium tetraborate solution containing 0.4 mg of boron/100 g bw. The serum decay of boron was followed and found to be monophasic. The data were interpreted according to a one-compartment open model. The appropriate pharmacokinetic parameters were estimated as follows: absorption half-life, t1/2a=0.608-0.432 hr; elimination half-life, t1/2=4.64-1.19 hr; volume of distribution, Vd=142.0-30.2 mL/100 g bw.; total clearance, Ctot=0.359 - 0.0285 mL/min/100 g bw. The maximum boron concentration in serum after administration (Cmax) was 2.13-0.270 mg/L, and the time needed to reach this maximum concentration (Tmax) was 1.76-0.887 hr. ...Results suggest that orally administered boric acid is rapidly and completely absorbed from the gastrointestinal tract into the blood stream. Boric acid in the intravascular space does not have a strong affinity to serum proteins, and rapidly diffuses to the extravascular space in proportion to blood flow without massive accumulation or binding in tissues. The main route of boron excretion from the body is via glomerular filtration. It may be inferred that there is partial tubular resorption at low plasma levels.

PMID:9765061 Usuda K et al; Arch Toxicol 72 (8): 468-74 (1998)


/Ten/ rats (n=10) were given a single oral injection of 2 mL of sodium tetraborate solution containing 0.4 mg of boron/100 g bw. The serum decay of boron was followed and found to be monophasic. The data were interpreted according to a one-compartment open model. The appropriate pharmacokinetic parameters were estimated as follows: absorption half-life, t1/2a=0.608-0.432 hr; elimination half-life, t1/2=4.64-1.19 hr; volume of distribution, Vd=142.0-30.2 mL/100 g bw.; total clearance, Ctot=0.359 - 0.0285 mL/min/100 g bw. The maximum boron concentration in serum after administration (Cmax) was 2.13-0.270 mg/L, and the time needed to reach this maximum concentration (Tmax) was 1.76-0.887 hr. ...Results suggest that orally administered boric acid is rapidly and completely absorbed from the gastrointestinal tract into the blood stream. Boric acid in the intravascular space does not have a strong affinity to serum proteins, and rapidly diffuses to the extravascular space in proportion to blood flow without massive accumulation or binding in tissues. The main route of boron excretion from the body is via glomerular filtration. It may be inferred that there is partial tubular resorption at low plasma levels.

PMID:9765061 Usuda K et al; Arch Toxicol 72 (8): 468-74 (1998)


Excretion occurs primarily in the urine.

Sheftel, V.O.; Indirect Food Additives and Polymers. Migration and Toxicology. Lewis Publishers, Boca Raton, FL. 2000., p. 852


5.3 Metabolism/Metabolites

No metabolic pathways reported.


5.4 Biological Half-Life

According to human cases of poisoning, the elimination half-life of boric acid ranges from 13 to 24 hours.


5.5 Mechanism of Action

Information regarding the mechanism of action of boric acid in mediating its antibacterial or antifungal actions is limited. Boric acid inhibits biofilm formation and hyphal transformation of _Candida albicans_, which are critical virulence factors. In addition, arrest of fungal growth was observed with the treatment of boric acid.


API SUPPLIERS

read-more
read-more
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Topical

read-more
read-more

01

DKSH

Switzerland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

Grade : Topical, Parenteral

Category : Solubilizers, Topical

02

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

03

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Grade : Topical

Category : Emulsifying Agents, Surfactant & Foaming Agents, Topical

05

arrow
ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

ASK US

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

Grade : Oral, Topical

Category : Solubilizers, Topical

06

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

07

arrow
Medlab Asia & Asia Health
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

09

Finar

India
Medlab Asia & Asia Health
Not Confirmed
arrow
click full view

Direct Compression

read-more
read-more

Taste Masking

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Granulation

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Emulsifying Agents

read-more
read-more

Empty Capsules

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Vegetarian Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Soft Gelatin

read-more
read-more

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty